Crizotinib Therapy for Advanced Lung Adenocarcinoma and a <i>ROS1</i> Rearrangement: Results From the EUROS1 Cohort

Mazières, Julien; Zalcman, Gérard; Crinò, Lucio; Biondani, Pamela; Barlési, Fabrice; Filleron, Thomas; C. Dingemans, Anne‐Marie; Léna, H.; Monnet, Isabelle; I. Rothschild, Sacha; Cappuzzo, Federico; Besse, Benjamin; Thiberville, Luc; Rouvière, Damien; Dziadziuszko, Rafał; F. Smit, Egbert; Wolf, Jürgen; Spirig, Christian; Pécuchet, Nicolas; Leenders, Frauke; M. Heuckmann, Johannes; Diebold, Joachim; Milia, Julie; K. Thomas, Roman; Gautschi, Oliver

doi:10.1200/jco.2014.58.3302

Public

Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

Published in Journal of Clinical Oncology • Feb 10, 2015

Authors:

Julien Mazières

Gérard Zalcman

Lucio Crinò

Abstract

PURPOSE: Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. PATIENTS AND METHODS: In the absence of a prospective clinical trial in Europe, we conducted a retrospective study in centers that teste...

Subject

Crizotinib

Medicine

ROS1

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!